Journal Information

Statistics

Follow this link to access the full text of the article

Case Letter
Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis
Camilla Chello, Alvise Sernicola, Giovanni Paolino, Teresa Grieco
Corresponding author
teresa.grieco@uniroma1.it

Corresponding author.
Dermatology Unit, Sapienza University of Rome, Rome, Italy
Read
6926
Times
was read the article
3028
Total PDF
3898
Total HTML
Share statistics
Article information
ISSN: 03650596
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 6 32 18 50
2025 5 141 64 205
2025 4 149 39 188
2025 3 158 57 215
2025 2 159 76 235
2025 1 109 62 171
2024 12 93 53 146
2024 11 110 69 179
2024 10 93 74 167
2024 9 127 97 224
2024 8 137 125 262
2024 7 118 123 241
2024 6 108 105 213
2024 5 81 69 150
2024 4 100 91 191
2024 3 101 83 184
2024 2 84 76 160
2024 1 86 50 136
2023 12 54 59 113
2023 11 62 84 146
2023 10 60 64 124
2023 9 72 76 148
2023 8 51 38 89
2023 7 58 46 104
2023 6 50 45 95
2023 5 46 25 71
2023 4 44 23 67
2023 3 41 64 105
2023 2 71 36 107
2023 1 66 38 104
2022 12 62 37 99
2022 11 86 62 148
2022 10 100 59 159
2022 9 82 78 160
2022 8 50 44 94
2022 7 61 71 132
2022 6 53 50 103
2022 5 38 40 78
2022 4 62 63 125
2022 3 68 67 135
2022 2 38 42 80
2022 1 70 82 152
2021 12 69 75 144
2021 11 85 63 148
2021 10 121 110 231
2021 9 121 82 203
2021 8 44 54 98
2021 7 27 20 47
Show all

Follow this link to access the full text of the article

Idiomas
Anais Brasileiros de Dermatologia
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.